UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 5, 2016
REGENXBIO INC.
(Exact Name of Registrant as Specified in its Charter)
|
Delaware |
|
001-37553 |
|
47-1851754 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
9712 Medical Center Drive, Suite 100 Rockville, Maryland |
20850 |
|
(Address of principal executive offices) |
(Zip Code) |
(240) 552-8181
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On August 9, 2016, REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended June 30, 2016. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8‑K and is incorporated by reference herein.
The information in Item 2.02 of this Current Report on Form 8‑K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
|
Item 5.02. |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On August 5, 2016, Camille Samuels, then a director of the Company, notified the Company’s Board of Directors (the “Board”) that she was resigning from the Board, effective immediately, so that she may devote her full time efforts to her other commitments. The Company and the Board wish to thank Ms. Samuels for her dedication and service to the Company.
On August 5, 2016, the Board, based upon the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Daniel J. Abdun-Nabi as a Class I director of the Company and a member of the Audit Committee of the Board, effective immediately. Mr. Abdun-Nabi’s initial term will expire at the Company’s 2019 annual meeting of stockholders. Mr. Abdun-Nabi was elected to fill a vacant seat on the Board following the departure of Ms. Samuels. The Board has determined that Mr. Abdun-Nabi is an independent director in accordance with applicable rules of the Securities and Exchange Commission and the NASDAQ Global Select Market.
Pursuant to the Company’s compensation program for non-employee directors, Mr. Abdun-Nabi was granted an option to purchase 25,000 shares of the Company’s common stock at an exercise price of $8.69 per share, the closing price per share of the common stock on August 5, 2016, the date on which he joined the Board. Such option will vest in equal monthly installments over a period of three years from the date of the grant, except that in the event of a change of control of the Company or death, the option will accelerate and become immediately exercisable. Mr. Abdun-Nabi will also receive a $35,000 annual retainer for his service on the Board and an additional $7,500 annual retainer for his service on the Audit Committee. In addition, he will be eligible to receive, upon the conclusion of each annual meeting of stockholders beginning in 2017, an option to purchase 12,500 shares of the Company’s common stock. Such annual option will vest in equal monthly installments over a period of one year from the date of grant, except that in the event of a change of control of the Company or death, the option will accelerate and become immediately exercisable. The compensation program for non-employee directors is described in further detail in the Company’s definitive proxy statement filed on April 18, 2016 in connection with the Company’s 2016 annual meeting of stockholders.
Mr. Abdun-Nabi and the Company have entered into an indemnification agreement requiring the Company to indemnify him to the fullest extent permitted under Delaware law with respect to his service as a director. The indemnification agreement is in the form entered into with the Company’s other directors and executive officers. This form is filed as Exhibit 10.1 to the Company’s Registration Statement on Form S-1 (File No. 333-206430), as originally filed on August 17, 2015 and declared effective on September 16, 2015.
A copy of a Company press release announcing the election of Mr. Abdun-Nabi and the departure of Ms. Samuels is attached hereto as Exhibit 99.2 and incorporated herein by reference.
|
Item 9.01. |
Financial Statements and Exhibits. |
(d)Exhibits
|
Exhibit No. |
Description |
||
|
99.1 |
Press Release dated August 9, 2016 relating to REGENXBIO Inc.’s financial results. |
||
|
99.2 |
Press Release dated August 8, 2016 relating to the election of Daniel J. Abdun-Nabi as a member of REGENXBIO Inc.’s Board of Directors. |
||
|
|
|
|
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
REGENXBIO INC. |
||
|
|
|
|||
|
Date: August 9, 2016 |
|
By: |
|
/s/ Kenneth T. Mills |
|
|
|
|
|
Kenneth T. Mills |
|
|
|
|
|
President and Chief Executive Officer |
|
Exhibit No. |
Description |
||
|
99.1 |
Press Release dated August 9, 2016 relating to REGENXBIO Inc.’s financial results. |
||
|
99.2 |
Press Release dated August 8, 2016 relating to the election of Daniel J. Abdun-Nabi as a member of REGENXBIO Inc.’s Board of Directors. |
||
|
|
|
|
|
Exhibit 99.1
REGENXBIO Reports Second Quarter 2016 Financial Results and Recent Operational Highlights
|
|
· |
On track to enroll first patients for Phase I/II clinical trial of RGX-501 for the treatment of homozygous familial hypercholesterolemia in the second half of 2016 |
|
|
· |
Received FDA Rare Pediatric Disease Designation for RGX-121 for the treatment of Mucopolysaccharidosis Type II |
|
|
· |
Entered into an exclusive license agreement with Biogen for the development of gene therapies for rare genetic vision disorders |
|
|
· |
$198.7 million in cash, cash equivalents and marketable securities as of June 30, 2016 |
ROCKVILLE, Md., August 9, 2016 -- REGENXBIO Inc. (Nasdaq: RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced financial results for the quarter ended June 30, 2016 and recent operational highlights.
“This quarter has seen great progress in the advancement and expansion of the pipeline of gene therapies based on our NAV Technology Platform through our internal development efforts and the activities of our NAV Technology Licensees,” said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO. “We look forward to enrolling the first patients in the RGX-501 Phase I/II clinical trial in the coming months, and expect to file INDs for our other three lead programs in 2017. Our NAV Technology Licensees continued their work to advance NAV-based gene therapies, with new progress reported by AveXis during the second quarter of 2016 in the treatment of spinal muscular atrophy using the NAV AAV9 vector, and the addition of our ninth licensee, Biogen, in a partnership that is focused on treatments for inherited blindness using NAV AAV8 and AAV9 vectors.”
Recent Operational Highlights
|
|
· |
REGENXBIO and trial sponsor the University of Pennsylvania are actively recruiting and screening participants in the Phase I/II clinical trial of RGX-501 for the treatment of homozygous familial hypercholesterolemia (HoFH), and remain on track to enroll the first patients in the second half of 2016. |
|
|
· |
REGENXBIO is in the process of completing preclinical studies for RGX-314 for the treatment of wet age-related macular degeneration (wet AMD) and plans to file an Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA) for a Phase I clinical trial in the first quarter of 2017. REGENXBIO plans to begin production to support this planned clinical trial in the third quarter of 2016. |
|
|
· |
REGENXBIO is conducting dose-ranging pre-clinical studies of RGX-111 in animals for the treatment of Mucopolysaccharidosis Type I (MPS I) to inform an optimal initial dosing plan for a first-in-human Phase I/II clinical trial. REGENXBIO plans to file an IND with the FDA in the U.S. and a Clinical Trial Application (CTA) with Health Canada for the Phase I/II clinical trial in the first half of 2017. |
|
|
· |
Rare Pediatric Disease Designation was granted to RGX-121 by the FDA in July 2016. REGENXBIO plans to file an IND with the FDA for a Phase I/II clinical trial in the first half of 2017 for the treatment of Mucopolysaccharidosis Type II (MPS II). |
|
|
· |
REGENXBIO entered into an exclusive license agreement with Biogen in May 2016 for the development of gene therapy treatments for rare genetic vision disorders. REGENXBIO received an undisclosed upfront payment and will receive ongoing fees, milestone payments and royalties on net sales of products incorporating the licensed intellectual property. |
|
|
· |
REGENXBIO expanded the organization to 81 full-time employees as of August 5, 2016, including an additional key executive dedicated to advancing its lead programs: |
|
|
o |
Sherri Van Everen, Pharm.D., Vice President, Medical Affairs |
|
|
§ |
More than 20 years of experience in medical affairs, including medical affairs strategy and initiatives, health economics and outcomes research. |
|
|
§ |
Previous positions include leading medical affairs activities as Executive Director of Scientific Collaborations at Avalanche Biotechnologies, Inc., and supportive medical affairs roles at Genentech, Inc., and Eli Lilly and Company. |
Financial Results
|
|
· |
Cash, cash equivalents and marketable securities as of June 30, 2016, were $198.7 million, compared to $216.4 million as of December 31, 2015. |
|
|
· |
Revenues were $2.4 million for the quarter ended June 30, 2016, compared to $1.4 million for the quarter ended June 30, 2015. |
|
|
· |
Total operating expenses were $17.3 million for the quarter ended June 30, 2016, compared to $7.7 million for the quarter ended June 30, 2015. |
|
|
· |
Net loss was $14.4 million, or $0.55 net loss per basic and diluted common share, for the quarter ended June 30, 2016, compared to $6.3 million, or $3.24 net loss per basic and diluted common share, for the quarter ended June 30, 2015. |
Financial Guidance
|
|
· |
REGENXBIO continues to expect full-year 2016 cash burn to be between $60 million and $70 million. |
About REGENXBIO
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third-party NAV Technology Platform licensees. As of June 30, 2016, REGENXBIO's NAV Technology Platform was being applied in the development of 29 product candidates for a variety of diseases, including five internally developed candidates and 24 partnered candidates developed by REGENXBIO's licensees.
Forward Looking Statements
This press release contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, REGENXBIO's research, development and regulatory plans for RGX-111, RGX-121, RGX-314, RGX-501 and other gene therapies. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could cause actual results to differ materially from those projected by such forward-looking statements. All of REGENXBIO’s development timelines could be subject to adjustment depending on recruitment rate, regulatory agency review and other factors that could delay the initiation and completion of clinical trials. Meaningful factors which could cause actual results to differ include, but are not limited to, the timing of enrollment, commencement and completion of REGENXBIO's clinical trials; the timing and success of preclinical studies and clinical trials conducted by REGENXBIO, its development partners and its NAV Technology Licensees; the ability to obtain and maintain regulatory approval to conduct clinical trials and to commercialize REGENXBIO's product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing REGENXBIO's product candidates; REGENXBIO's ability to obtain and maintain intellectual property protection for our product candidates and technology; trends and challenges in REGENXBIO's business and the markets in which REGENXBIO operates; REGENXBIO's ability to attract or retain key personnel; the size and growth of the potential markets for REGENXBIO's product candidates and the ability to serve those markets; the rate and degree of market acceptance of any of REGENXBIO's product candidates; REGENXBIO's ability to establish and maintain development partnerships, including those with NAV Technology Licensees; REGENXBIO's expenses and revenue, the sufficiency of REGENXBIO's cash resources and needs for additional financing, regulatory developments in
the United States and foreign countries, as well as other factors discussed in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, which are available on the SEC's website at www.sec.gov. Additional factors may be set forth in those sections of REGENXBIO's Form 10-Q for the quarter ended June 30, 2016, to be filed with the SEC in the third quarter of 2016. In addition to the risks described above and in REGENXBIO's filings with the SEC, other unknown or unpredictable factors also could affect REGENXBIO's results. There can be no assurance that the actual results or developments anticipated by REGENXBIO will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, REGENXBIO. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.
All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. REGENXBIO cautions investors not to rely too heavily on the forward-looking statements REGENXBIO makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). REGENXBIO undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
BALANCE SHEETS
(unaudited)
(in thousands)
|
|
|
June 30, 2016 |
|
|
December 31, 2015 |
|
||
|
Assets |
|
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
30,083 |
|
|
$ |
54,116 |
|
|
Marketable securities |
|
|
64,124 |
|
|
|
60,025 |
|
|
Accounts receivable |
|
|
783 |
|
|
|
2,136 |
|
|
Prepaid expenses |
|
|
1,480 |
|
|
|
1,020 |
|
|
Other current assets |
|
|
1,437 |
|
|
|
851 |
|
|
Total current assets |
|
|
97,907 |
|
|
|
118,148 |
|
|
Marketable securities |
|
|
104,510 |
|
|
|
102,226 |
|
|
Property and equipment, net |
|
|
2,864 |
|
|
|
538 |
|
|
Cost method investments |
|
|
300 |
|
|
|
300 |
|
|
Restricted cash |
|
|
225 |
|
|
|
— |
|
|
Other assets |
|
|
266 |
|
|
|
168 |
|
|
Total assets |
|
$ |
206,072 |
|
|
$ |
221,380 |
|
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
2,076 |
|
|
$ |
1,014 |
|
|
Accrued expenses and other current liabilities |
|
|
7,073 |
|
|
|
3,198 |
|
|
Advance payments |
|
|
— |
|
|
|
127 |
|
|
Total current liabilities |
|
|
9,149 |
|
|
|
4,339 |
|
|
Deferred rent, net of current portion |
|
|
748 |
|
|
|
233 |
|
|
Total liabilities |
|
|
9,897 |
|
|
|
4,572 |
|
|
Stockholders’ equity |
|
|
196,175 |
|
|
|
216,808 |
|
|
Total liabilities and stockholders’ equity |
|
$ |
206,072 |
|
|
$ |
221,380 |
|
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(unaudited)
(in thousands, except per share data)
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
|
2016 |
|
|
2015 |
|
|
2016 |
|
|
2015 |
|
||||
|
Revenues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
License revenue |
|
$ |
2,245 |
|
|
$ |
470 |
|
|
$ |
2,573 |
|
|
$ |
570 |
|
|
License revenue from related party |
|
|
— |
|
|
|
1,000 |
|
|
|
— |
|
|
|
1,000 |
|
|
Reagent sales |
|
|
107 |
|
|
|
44 |
|
|
|
166 |
|
|
|
148 |
|
|
Grant revenue |
|
|
23 |
|
|
|
(151 |
) |
|
|
29 |
|
|
|
289 |
|
|
Total revenues |
|
|
2,375 |
|
|
|
1,363 |
|
|
|
2,768 |
|
|
|
2,007 |
|
|
Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Costs of revenues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Licensing costs (including amounts to related parties) |
|
|
449 |
|
|
|
294 |
|
|
|
515 |
|
|
|
314 |
|
|
Costs of reagent sales (including amounts to related |
|
|
49 |
|
|
|
16 |
|
|
|
79 |
|
|
|
49 |
|
|
Research and development (including amounts to related |
|
|
10,680 |
|
|
|
4,012 |
|
|
|
16,863 |
|
|
|
6,803 |
|
|
General and administrative (including amounts to related |
|
|
6,169 |
|
|
|
3,397 |
|
|
|
11,648 |
|
|
|
5,113 |
|
|
Other operating expenses (income) |
|
|
(20 |
) |
|
|
(60 |
) |
|
|
(134 |
) |
|
|
17 |
|
|
Total operating expenses |
|
|
17,327 |
|
|
|
7,659 |
|
|
|
28,971 |
|
|
|
12,296 |
|
|
Loss from operations |
|
|
(14,952 |
) |
|
|
(6,296 |
) |
|
|
(26,203 |
) |
|
|
(10,289 |
) |
|
Other Income (Expense) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investment income |
|
|
515 |
|
|
|
6 |
|
|
|
998 |
|
|
|
8 |
|
|
Interest expense |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(20 |
) |
|
Total other income (expense) |
|
|
515 |
|
|
|
6 |
|
|
|
998 |
|
|
|
(12 |
) |
|
Net loss |
|
$ |
(14,437 |
) |
|
$ |
(6,290 |
) |
|
$ |
(25,205 |
) |
|
$ |
(10,301 |
) |
|
Other Comprehensive Income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized gain on available-for-sale securities |
|
|
246 |
|
|
|
— |
|
|
|
1,240 |
|
|
|
— |
|
|
Total other comprehensive income |
|
|
246 |
|
|
|
— |
|
|
|
1,240 |
|
|
|
— |
|
|
Comprehensive loss |
|
$ |
(14,191 |
) |
|
$ |
(6,290 |
) |
|
$ |
(23,965 |
) |
|
$ |
(10,301 |
) |
|
Reconciliation of net loss to net loss applicable to |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(14,437 |
) |
|
$ |
(6,290 |
) |
|
$ |
(25,205 |
) |
|
$ |
(10,301 |
) |
|
Net accretion and dividends on convertible preferred stock |
|
|
— |
|
|
|
(2,502 |
) |
|
|
— |
|
|
|
(1,747 |
) |
|
Net gain on extinguishment of convertible preferred stock |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
759 |
|
|
Net loss applicable to common stockholders |
|
$ |
(14,437 |
) |
|
$ |
(8,792 |
) |
|
$ |
(25,205 |
) |
|
$ |
(11,289 |
) |
|
Basic and diluted net loss per common share |
|
$ |
(0.55 |
) |
|
$ |
(3.24 |
) |
|
$ |
(0.96 |
) |
|
$ |
(4.21 |
) |
|
Weighted-average basic and diluted common shares |
|
|
26,362 |
|
|
|
2,712 |
|
|
|
26,344 |
|
|
|
2,679 |
|
###
CONTACT:
Investors
Elizabeth Broder, 646-378-2945
ebroder@troutgroup.com
Media
Laura Bagby, 312-448-8098
lbagby@6degreespr.com
Exhibit 99.2
Daniel J. Abdun-Nabi Appointed to REGENXBIO Board of Directors
ROCKVILLE, Md., August 8, 2016 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced the appointment of Daniel J. Abdun-Nabi to its board of directors, effective as of August 5, 2016.
"Dan is an experienced biopharmaceutical leader who brings to REGENXBIO more than 25 years of success in key strategic, operational, legal and board roles," said Don Hayden, Chairman of REGENXBIO’s board of directors. "We are excited to have Dan join the board at this important point in the growth and development of the company."
Mr. Abdun-Nabi has served as President and Chief Executive Officer of Emergent BioSolutions Inc. since April 2012. Since joining Emergent in 2004, he has held several senior leadership positions including Chief Operating Officer and General Counsel. Prior to joining Emergent, Mr. Abdun-Nabi served as General Counsel for IGEN International, Inc., and as Senior Vice President - Legal Affairs, General Counsel and Secretary at North American Vaccine, Inc. Mr. Abdun-Nabi received a Master of Laws in taxation from Georgetown University Law Center, a J.D. from the University of San Diego School of Law and a B.A. in political science from the University of Massachusetts, Amherst.
“REGENXBIO’s proprietary NAV Technology Platform has ushered in a new era of gene therapy innovation with the potential to transform the lives of patients suffering from serious diseases with unmet needs,” said Mr. Abdun-Nabi. “I look forward to contributing to REGENXBIO’s continued success as the company advances its gene therapy treatments into clinical development.”
In addition, REGENXBIO announced that Camille Samuels resigned from its board of directors on August 5, 2016. “I would like to recognize and thank Camille for her sound guidance and many contributions as an early investor in REGENXBIO,” said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO. “Camille played an instrumental role in the growth of the company and recognized the opportunity for our NAV Technology Platform to improve the lives of patients.”
About REGENXBIO
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third-party NAV Technology Platform licensees. As of March 31, 2016, REGENXBIO's NAV Technology Platform was being applied in the development of 28 product candidates for a variety of diseases, including five internally developed candidates and 23 partnered candidates developed by REGENXBIO's licensees.
Forward Looking Statements
This press release contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, REGENXBIO's research, development and regulatory plans for its gene therapy treatments. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could cause actual results to differ materially from those projected by such forward-looking statements. All of REGENXBIO’s development timelines could be subject to adjustment depending on recruitment rate, regulatory agency review and other factors that could delay the initiation and completion of clinical trials. Meaningful factors which could cause actual results to differ include, but are not limited to, the timing of enrollment, commencement and completion of REGENXBIO's clinical trials; the timing and success of preclinical studies and clinical trials conducted by REGENXBIO, its development partners and its NAV Technology Licensees; the ability to obtain and maintain regulatory approval to conduct clinical trials and to commercialize REGENXBIO's product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing REGENXBIO's product candidates; REGENXBIO's ability to obtain and maintain intellectual property protection for our product
candidates and technology; trends and challenges in REGENXBIO's business and the markets in which REGENXBIO operates; REGENXBIO's ability to attract or retain key personnel; the size and growth of the potential markets for REGENXBIO's product candidates and the ability to serve those markets; the rate and degree of market acceptance of any of REGENXBIO's product candidates; REGENXBIO's ability to establish and maintain development partnerships, including those with NAV Technology Licensees; REGENXBIO's expenses and revenue, the sufficiency of REGENXBIO's cash resources and needs for additional financing, regulatory developments in the United States and foreign countries, as well as other factors discussed in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, which are available on the SEC's website at www.sec.gov. Additional factors may be set forth in those sections of REGENXBIO's Form 10-Q for the quarter ended June 30, 2016, to be filed with the SEC in the third quarter of 2016. In addition to the risks described above and in REGENXBIO's filings with the SEC, other unknown or unpredictable factors also could affect REGENXBIO's results. There can be no assurance that the actual results or developments anticipated by REGENXBIO will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, REGENXBIO. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.
All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. REGENXBIO cautions investors not to rely too heavily on the forward-looking statements REGENXBIO makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). REGENXBIO undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
###
CONTACT:
Investors
Elizabeth Broder, 646-378-2945
ebroder@troutgroup.com
Media
Laura Bagby, 312-448-8098
lbagby@6degreespr.com